



truscreen  
a world without  
cervical cancer

16 August 2024

## Annual Meeting

**Dear fellow Shareholder,**

I am pleased to invite shareholders to the 2024 Annual Meeting (AM) of TruScreen Group Limited scheduled for 3 September 2024.

The details of the Annual Meeting are as follows:

To be held in the Boardroom of Link Market Services, Level 30 PWC Tower 15 Customs Street West Auckland and online at <https://www.virtualmeeting.co.nz/tru24>

Shareholders attending and participating in the Annual Meeting in person or virtually via the online platform will be able to vote and ask questions during the meeting. More information regarding virtual attendance at the Annual Meeting (including how to vote and ask questions virtually during the Meeting) is available in the Virtual General Meeting Online Portal Guide available at

<https://bcast.linkinvestorservices.co.nz/generic/docs/OnlinePortalGuide.pdf>

Date: 3 September 2024

Time; 11.00am Auckland, New Zealand time.

Accompanying this letter is a Notice of the Annual Meeting and a Proxy Form which must be lodged at least 48 hours before the meeting.

Please note that this meeting is restricted to registered shareholders and/or proxy holders.

Yours sincerely,

Anthony Ho  
Chairman



truscreen  
a world without  
cervical cancer

For more information, visit [www.truscreen.com](http://www.truscreen.com) or contact:

Mr Martin Dillion

Guy Robertson

Chief Executive Officer

Chief Financial Officer

[Martindillon@truscreen.com](mailto:Martindillon@truscreen.com)

[guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)

### About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra®, is registered as a primary screening tool for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Zimbabwe, Israel, Ukraine, and the Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology has been endorsed in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.

TruScreen has been recognised in a China Blue Paper "Cervical Cancer Three Stage Standardized Prevent and Treatment" published on 28 April 2023.

To date, over 170000\* examinations have been performed with TruScreen device and over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer®".

To learn more, please visit: [www.truscreen.com/](http://www.truscreen.com/).

*\*Based on Single Use Sensor sales.*